{
    "clinical_study": {
        "@rank": "31916", 
        "arm_group": [
            {
                "arm_group_label": "HM11260C (8 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Monthly administration of 8 mg of HMC11260C by subcutaneous injection for 16 weeks"
            }, 
            {
                "arm_group_label": "HM11260C (12 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Monthly administration of 12 mg of HMC11260C by subcutaneous injection for 16 weeks"
            }, 
            {
                "arm_group_label": "HM11260C (16 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Monthly administration of 16 mg of HMC11260C by subcutaneous injection for 16 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Monthly administration of placebo by subcutaneous injection for 16 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the optimal dose or doses of HM11260C, when\n      administered once a month under the skin, to improve the control of blood sugar levels in\n      patients with early-stage type 2 diabetes mellitus (T2DM)."
        }, 
        "brief_title": "Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ages eligible for study : 18 years to 74 years\n\n          -  Genders eligible for study : Male and Female\n\n          -  Diagnosed with T2DM\n\n          -  Taking a stable dose of metformin monotherapy\n\n          -  HbA1c levels of between \u2265 7.0% and \u2264 10.0%\n\n          -  Females of childbearing potential who are not pregnant and agree to use a reliable\n             method of birth control\n\n          -  Written informed consent must be obtained\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing (lactating) women\n\n          -  Diagnosis of type 1 diabetes mellitus\n\n          -  Uncontrolled diabetes defined as a FPG level of > 240 mg/dL at screening\n\n          -  A significant change in body weight in the 3 months before screening\n\n          -  Any history of GI intolerance\n\n          -  Personal or family history of medullary thyroid cancer (MTC) or a genetic condition\n             that predisposes to MTC\n\n          -  Known history of acute or chronic pancreatitis\n\n          -  A history of alcohol or drug abuse or drug addiction"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081118", 
            "org_study_id": "HM-EXC-204"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HM11260C (8 mg)", 
                    "HM11260C (12 mg)", 
                    "HM11260C (16 mg)"
                ], 
                "description": "HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)", 
                "intervention_name": "HM11260C", 
                "intervention_type": "Drug", 
                "other_name": "LAPS-Exendin-4"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo for HM11260C", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Exenatide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "contact": {
                "email": "clinical4@hanmi.co.kr", 
                "last_name": "Hanmi Pharmaceutical"
            }, 
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida"
                }, 
                "name": "Hanmi pharmaceutical"
            }, 
            "investigator": {
                "last_name": "Hanmi Pharmaceutical", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin", 
        "other_outcome": [
            {
                "measure": "Number of Participants with Adverse Events by HM11260C", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 155"
            }, 
            {
                "measure": "Number of Participants with Immunogenicity by HM11260C", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 155"
            }
        ], 
        "overall_contact": {
            "email": "clinical4@hanmi.co.kr", 
            "last_name": "Hanmi Pharmaceutical"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in baseline in glycosylated haemoglobin (HbA1c) at 16 weeks", 
            "safety_issue": "No", 
            "time_frame": "Up to day 155"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081118"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Fasting plasma glucose levels (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Up to day 155"
            }, 
            {
                "measure": "7-point glucose profile", 
                "safety_issue": "No", 
                "time_frame": "Up to day 155"
            }, 
            {
                "measure": "Serum lipid profile", 
                "safety_issue": "No", 
                "time_frame": "Up to day 155"
            }, 
            {
                "measure": "Body weight", 
                "safety_issue": "No", 
                "time_frame": "Up to day 155"
            }, 
            {
                "measure": "Fasting insulin", 
                "safety_issue": "No", 
                "time_frame": "Up to day 155"
            }, 
            {
                "measure": "C-peptide", 
                "safety_issue": "No", 
                "time_frame": "Up to day 155"
            }, 
            {
                "measure": "Glucagon", 
                "safety_issue": "No", 
                "time_frame": "Up to day 155"
            }, 
            {
                "measure": "Glycated albumin", 
                "safety_issue": "No", 
                "time_frame": "Up to day 155"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}